CQToday is reporting that an HHS task force designed to study the effects of drug re-importation from foreign countries has concluded such a move would only save 1-2% and "would likely adversely affect incentives for research and development".

The task force was created in the wake of the Medicare Prescription Drug Law enacted this year, and was composed of officials from HHS, the Food and Drug Administration, and other government agencies.